USANA Health (USNA) Upgraded to Buy: Here's What You Should Know

Core Viewpoint - USANA Health Sciences (USNA) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on an upward trend in earnings estimates, which significantly influences stock prices [1][4]. Earnings Estimates and Stock Ratings - The Zacks rating system is primarily driven by changes in a company's earnings picture, with the Zacks Consensus Estimate tracking EPS estimates from sell-side analysts [2]. - The correlation between earnings estimate revisions and near-term stock price movements makes the Zacks rating system valuable for investors, as it provides a clearer picture than subjective Wall Street analyst ratings [3][7]. Institutional Investor Influence - Institutional investors play a role in the relationship between earnings estimates and stock prices, as they adjust their valuations based on these estimates, leading to significant stock transactions that affect price movements [5]. Business Improvement Indicators - Rising earnings estimates and the Zacks rating upgrade for USANA Health suggest an improvement in the company's underlying business, which could lead to increased stock prices as investors respond positively [6]. Earnings Estimate Revisions for USANA Health - For the fiscal year ending December 2025, USANA Health is expected to earn $2.61 per share, with no year-over-year change, but the Zacks Consensus Estimate has increased by 1.8% over the past three months [9]. Zacks Rank System Performance - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - The upgrade of USANA Health to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [11].